Novel inhibitors of human CMV.

Novel inhibitors of human CMV. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Novel inhibitors of human CMV. Abstract Text:

Graciela Andrei,Eric De Clercq,Robert Snoeck,

Human CMV (HCMV) is an opportunistic pathogen associated with significant morbidity and mortality among immunocompromised patients (in particular immunosuppressed patients with stem cell or solid organ transplantation, AIDS or cancer). Additionally, congenital HCMV infections are a leading cause of birth defects and infections in children, occurring in 1 to 2% of all live births. Drugs currently available for the treatment of HCMV diseases in the immunocompromised individual include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. Although these drugs have proved successful in the management of HCMV disease in immunocompromised patients, their use is limited because of toxicity, poor oral bioavailability, modest efficacy and the development of drug resistance. Furthermore, no drug has been licensed for use in the treatment of congenital HCMV. Therefore, there is a need to develop new compounds against HCMV diseases. The search for novel inhibitors of HCMV replication has led to the identification of new molecular targets such as the viral protein kinase UL97, and the viral proteins involved in genome replication or in DNA maturation and egress. Moreover, a new strategy based on the identification of specific cellular targets required for viral replication has been developed. This review focuses on non-nucleoside compounds that inhibit specific viral processes and on cell-based approaches that result in the selective inhibition of virus replication.

Novel inhibitors of human CMV. Publishing Authors By Initials

G Andrei,E De Clercq,R Snoeck,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Novel inhibitors of human CMV. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current opinion in investigational drugs (London,

VOLUME: 9

Page Numbers: 132-45

Journal Abbreviation:

ISSN: 1472-4472

DAY: 4

MONTH: Feb

YEAR: 2008

Novel inhibitors of human CMV. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100965718

Novel inhibitors of human CMV. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Novel inhibitors of human CMV. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Novel inhibitors of human CMV.

AFFILIATION: Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, KU Leuven, Belgium. robert.snoeck@rega.kuleuven.ac.be.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Investig Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Novel inhibitors of human CMV Related Publications

• Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
• Duchenne muscular dystrophy: Which is the best anesthetic agent?
• Ester prodrugs of cyclic 1-(S)- [3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
• Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus.
• In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.
• Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
• Mapping inelastic intensities in diffraction patterns of magnetic samples using the energy spectrum imaging technique.
• Nanoscale holographic interferometry for strain measurements in electronic devices.
• Novel inhibitors of human CMV.
• Rh-gene frequencies in pygmies (Batswa) of the Belgian Congo.
• Stabilization of metastable phases in spatially restricted fields: the case of the Fe2O3 polymorphs.
• [Not Available.]
• [Not Available.]